Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam-nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.
['Shields|Ryan K|RK|', 'McCreary|Erin K|EK|', 'Marini|Rachel V|RV|', 'Kline|Ellen G|EG|', 'Jones|Chelsea E|CE|', 'Hao|Binghua|B|', 'Chen|Liang|L|', 'Kreiswirth|Barry N|BN|', 'Doi|Yohei|Y|', 'Clancy|Cornelius J|CJ|', 'Nguyen|M Hong|MH|']
D000900:Anti-Bacterial Agents D001426:Bacterial Proteins D001897:Boronic Acids D000073182:Carbapenem-Resistant Enterobacteriaceae D004756:Enterobacteriaceae Infections D006801:Humans D007711:Klebsiella pneumoniae D000077731:Meropenem D008826:Microbial Sensitivity Tests D001618:beta-Lactamases
porin KPC meropenem resistance vaborbactam